On Friday, Shares of St. Jude Medical, Inc. (NYSE:STJ), lost -0.39% to $70.94.
St. Jude Medical, stated sales and net earnings for its second quarter ended July 4, 2015.
Second quarter 2015 highlights:
Net sales raised by about 6 percent on a constant currency basis contrast to the preceding year quarter
CardioMEMS HF System sales totaled about $20 million
Atrial fibrillation revenue raised by about 18 percent on a constant currency basis due to global market share gains driven by the St. Jude Medical FlexAbilityTM and TactiCathTM Quartz Contact Force ablation catheters
Worldwide neuromodulation revenue raised by about 17 percent on a constant currency basis, marking the fourth successive quarter of sales acceleration on a year over year basis
Second Quarter 2015 Sales
The company stated net sales of $1.410 billion in the second quarter of 2015, a 3 percent decrease contrast to net sales of $1.448 billion in the second quarter of 2014. On a constant currency basis, net sales raised by about 6 percent contrast to the second quarter of 2014.
Commenting on the company’s financial results, St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, “St. Jude Medical’s second quarter results reflect the continued success of our innovation-based growth strategy. We remain confident in our key programs that accelerated sales growth in the first half of 2015 and are raising our sales guidance in order to demonstrate our strong outlook for the remainder of the year.”
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide.
Shares of Centene Corp (NYSE:CNC), declined -0.98% to $69.43, during its last trading session.
Centene Corporation, and Health Net, declared early termination of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with their merger agreement under which Centene will acquire all of the shares of Health Net in a cash and stock transaction valued at about $6.8 billion, counting the assumption of about $500 million of debt.
As formerly declared on July 2, 2015, the combination of Centene and Health Net would create a leading diversified multi-national health care enterprise, extending Centene’s offerings in government programs, counting Medicare Advantage and programs offered through contracts with the U.S. Department of Defense and U.S. Department of Veterans Affairs, in addition to the commercial exchanges.
Centene continues to expect that the transaction will close by early 2016, subject to approval by Centene and Health Net shareholders, approvals by relevant state insurance and health care regulators, and other customary closing conditions.
Centene Corporation operates as a diversified, multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. It operates in two segments, Managed Care and Specialty Services.
At the end of Friday’s trade, Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), gained 4.05% to $17.98.
Aegerion Pharmaceuticals declared that on August 3, 2015, Aegerion granted stock options to purchase an aggregate of 283,325 shares of common stock to nine new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $19.58, the closing price of Aegerion’s common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion’s Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
In January 2015, Aegerion’s Board of Directors approved the reservation of 750,000 shares of common stock to be used through the end of 2015 exclusively for the grant of non-qualified stock options to individuals who were not formerly an employee or non-employee director of Aegerion (or following a bona fide period of non-employment), as an inducement new hire stock option award material to an individual’s entry into employment within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (Inducement Stock Options).
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or attained generalized lipodystrophy.
Finally, WhiteWave Foods Co (NYSE:WWAV), ended its last trade with -0.32% loss, and closed at $49.69.
WhiteWave Foods Company stated record results for the second quarter ended June 30, 2015.
WhiteWave stated second quarter 2015 adjusted diluted earnings per share of $0.26, not taking into account operating investments associated with its China joint venture. Counting joint venture investments, WhiteWave stated second quarter 2015 adjusted diluted earnings per share of $0.24.
Net sales for second quarter 2015 were $924 million, a 10 percent enhance from net sales of $838 million in second quarter 2014. These results were driven by strong growth across the Americas Foods & Beverages and Europe Foods & Beverages segments and a benefit from the inclusion of So Delicious Dairy Free ® that was attained in fourth quarter 2014. On a constant currency basis, net sales raised 14 percent in second quarter 2015 over the same period in 2014. Not taking into account acquisitions, organic constant currency net sales raised 9 percent in second quarter 2015 over the same period in 2014.
The WhiteWave Foods Company, a consumer packaged food and beverage company, manufactures, markets, distributes, and sells branded plant-based foods and beverages, salads, fruits and vegetables, coffee creamers and beverages, and dairy products and organic produce in North America and Europe.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
